Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1998 Mar;42(3):703-4.
doi: 10.1128/AAC.42.3.703.

In vitro activity of BAY 12-8039, a new fluoroquinolone against mycoplasmas

C M Bébéar  1 , H Renaudin, A Boudjadja, C Bébéar
Affiliations

In vitro activity of BAY 12-8039, a new fluoroquinolone against mycoplasmas

C M Bébéar et al. Antimicrob Agents Chemother. 1998 Mar.

Abstract

The in vitro activity of the fluoroquinolone BAY 12-8039 against 66 strains of different mycoplasma species and 30 strains of Ureaplasma urealyticum was compared with those of three other antimicrobial agents. BAY 12-8039 at 0.5 microg/ml inhibited 100% of all the mycoplasmal and ureaplasmal strains tested. The minimal bactericidal concentrations of BAY 12-8039 increased only two- to eightfold compared to the MICs. Furthermore, they were comparable to those of sparfloxacin and lower than those of doxycycline and clarithromycin.

PubMed Disclaimer

References

    1. Aldridge K E, Ashcraft D. Comparison of the in vitro activities of BAY 12-8039, a new quinolone, and other antimicrobials against clinically important anaerobes. Antimicrob Agents Chemother. 1997;41:709–711. - PMC - PubMed
    1. Bébéar C, Cantet P, Renaudin H, Quentin C. Activité comparée de la minocycline et doxycycline sur les mycoplasmes pathogénes pour l’homme. Pathol Biol. 1985;33:577–580. - PubMed
    1. Bebear C M, Bové J M, Bebear C, Renaudin J. Characterization of Mycoplasma hominis mutations involved in resistance to fluoroquinolones. Antimicrob Agents Chemother. 1997;41:269–273. - PMC - PubMed
    1. Kaku M, Ishida K, Irifune K, Mizukane R, Takemura H, Yoshida R, Tanaka H, Usui T, Tomono K, Suyama N, Koga H, Kohno S, Hara K. In vitro and in vivo activities of sparfloxacin against Mycoplasma pneumoniae. Antimicrob Agents Chemother. 1994;38:738–741. - PMC - PubMed
    1. Kenny G E, Cartwright F D. Susceptibilities of Mycoplasma hominis, Mycoplasma pneumoniae, and Ureaplasma urealyticum to a new quinolone, OPC 17116. Antimicrob Agents Chemother. 1993;36:1726–1727. - PMC - PubMed

Publication types

LinkOut - more resources